In addition, studies have demonstrated that IL-17C is expressed in the skin of patients with atopic dermatitis, and that the treatment with therapeutic antibodies directed against IL-17C decreased skin inflammation in IL-23- and calcipotriol-dependent mouse models of psoriasis and atopic dermatitis, respectively [5,6,8]. Here, IL17C is linked to atopic eczema.